SYMLIN Market Opportunity United States
Source: ADA, Amylin internal data
US SYMLIN Target 4.5 million
TOTAL Diabetes US: 16.1 million people
Population growth ~ 3% each year
Strong trend to more intensive management
SALES & MARKETING
2 doses
per day
2.8 M
3 doses
per day
0.9 M
Previous slide
Next slide
Back to first slide
View graphic version